HCW Biologics Inc (HCWB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HCW Biologics Inc (HCWB) has a cash flow conversion efficiency ratio of -1.214x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.36 Million) by net assets ($2.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HCWB equity financing ratio to measure how much of total assets are equity-financed.
HCW Biologics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how HCW Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check HCWB cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
HCW Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HCW Biologics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jost AG
MU:JOX
|
N/A |
|
Dialight plc
LSE:DIA
|
0.032x |
|
Easson Holdings Ltd
PA:MLEAS
|
N/A |
|
Volta Finance Ltd
LSE:VTAS
|
0.113x |
|
Globavend Holdings Limited Ordinary Shares
NASDAQ:GVH
|
0.038x |
|
M&G Credit Income Investment Trust PLC
LSE:MGCI
|
0.028x |
|
Galeo Concept SA
PA:MLGAL
|
N/A |
|
Yimutian Inc. American Depositary Shares
NASDAQ:YMT
|
0.001x |
Annual Cash Flow Conversion Efficiency for HCW Biologics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of HCW Biologics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market value of HCW Biologics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.76 Million | $-13.39 Million | -4.844x | -330.49% |
| 2024-12-31 | $-6.77 Million | $-14.23 Million | 2.101x | +225.65% |
| 2023-12-31 | $13.46 Million | $-22.51 Million | -1.672x | -502.70% |
| 2022-12-31 | $37.43 Million | $-10.39 Million | -0.277x | -29.43% |
| 2021-12-31 | $51.19 Million | $-10.98 Million | -0.214x | +70.41% |
| 2020-12-31 | $14.40 Million | $-10.43 Million | -0.725x | +3.61% |
| 2019-12-31 | $9.00 Million | $-6.77 Million | -0.752x | -- |
About HCW Biologics Inc
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and … Read more